Eprosartan

Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It is marketed in the United States as Teveten by Abbvie, the spin-off of the pharmaceutical discovery division of Abbott Laboratories; it is marketed as Eprozar by Intas Pharmaceuticals in India, and by Abbott Laboratories elsewhere. The compound came into the Abbott Laboratories cardiovascular pipeline with its acquisition of Kos Pharmaceuticals in 2006, which had licensed it, along with "a range of hypertensive treatments", from the Biovail Corporation.[1]

Eprosartan

Clinical data
Trade names	Teveten
AHFS/Drugs.com	Monograph
MedlinePlus	a601237
Routes of administration	Oral
ATC code	C09CA02 (WHO)
Pharmacokinetic data
Bioavailability	15% (Eprosartan mesylate)
Metabolism	not metabolized
Elimination half-life	5 to 9 hours
Excretion	Renal 10%, biliary 90%
Identifiers
IUPAC name 4-({2-Butyl-5-[2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid
CAS Number	133040-01-4^Y
PubChem CID	5281037
IUPHAR/BPS	588
DrugBank	DB00876^Y
ChemSpider	4444504^Y
UNII	2KH13Z0S0Y
KEGG	D04040^Y
ChEBI	CHEBI:4814^Y
ChEMBL	ChEMBL813^Y
CompTox Dashboard (EPA)	DTXSID0022989
Chemical and physical data
Formula	C23H24N2O4S
Molar mass	Eprosartan mesylate: 520.625 g/mol g·mol^−1
3D model (JSmol)	Interactive image
SMILES O=C(O)\C(=C\c1cnc(n1Cc2ccc(C(=O)O)cc2)CCCC)Cc3sccc3
InChI InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+^Y Key:OROAFUQRIXKEMV-LDADJPATSA-N^Y
(verify)

Eprosartan is sometimes paired with hydrochlorothiazide, whereupon it is marketed in the US as Teveten HCT and elsewhere as Teveten Plus.

The drug acts on the renin–angiotensin system to decrease total peripheral resistance in two ways. First, it blocks the binding of angiotensin II to AT₁ receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure.

As with other angiotensin II receptor antagonists, eprosartan is generally better tolerated than enalapril (an ACE inhibitor), especially among the elderly.[2]

See also

• Discovery and development of angiotensin receptor blockers

References

1. Anon., 2006, Abbott Laboratories: Kos Pharmaceuticals a wise buy, Datamonitor ResearchStore (online), November 8, 2006, see , accessed 29 January 2015.
2. Ruilope L, Jäger B, Prichard B (2001). "Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial". Blood Press. 10 (4): 223–9. doi:10.1080/08037050152669747. PMID 11800061.